Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y2D4
UPID:
EXC6B_HUMAN
Alternative names:
Exocyst complex component Sec15B; SEC15-like protein 2
Alternative UPACC:
Q9Y2D4; B8ZZY3
Background:
Exocyst complex component 6B, also known as Sec15B or SEC15-like protein 2, plays a crucial role in cellular processes as a part of the exocyst complex. This complex is essential for the docking of exocytic vesicles with fusion sites on the plasma membrane, facilitating the precise delivery of cellular cargo.
Therapeutic significance:
Linked to Spondyloepimetaphyseal dysplasia with joint laxity, 3, a rare bone disorder, understanding the role of Exocyst complex component 6B could open doors to potential therapeutic strategies. Its involvement in cellular transport mechanisms makes it a target for research into treatments for this and potentially other related disorders.